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Background: It is not clear how invading autoreactive T cells initiate the pathogenic process inside the diseased
organ in T cell-mediated organ-specific autoimmune disease. In experimental autoimmune uveitis (EAU) induced
by adoptive transfer of interphotoreceptor retinoid-binding protein (IRBP)-specific T cells in mice, we have previously
reported that intraocular inflammation was initiated by infiltrating IRBP-specific T cells that directly interacted with
retinal cells and resulted in the active release of high mobility group box 1 (HMGB1), an important member of damage
associate molecular patterns (DAMPs). Furthermore, blockade of HMGB1 in our murine model reduced intraocular
inflammation via suppression of IRBP-specific T cell functions. These results have demonstrated that HMGB1 is an early
and critical mediator of induction of intraocular inflammation. The present study identified the cell surface molecule
that triggers HMGB1 secretion.
Methods: Retinal explants from Fas-deficient (Faslpr) and wild-type (Wt) C57BL/6 (B6) mice were cultured with
activated IRBP 1–20 peptide-specific T cells or with a Fas-activating antibody (Jo2), and then the level of HMGB1 in
culture supernatants were detected by ELISA. In addition, released HMGB1 was examined in the eye of Faslpr and Wt
mice after IRBP-specific T cell transfer. Uveitis was evaluated in the IRBP-specific T cell transferred Faslpr mice after
recombinant HMGB1 was restored within the eye and in the IRBP-specific T cell transferred Wt mice after they were
treated with a Fas antagonist (Met12).
Results: In contrast to retinal explants from Wt mice, those from Faslpr mice did not release HMGB1 after exposure to
IRBP-specific T cells or to Jo2. The release of HMGB1 by Wt retinal explants was suppressed by Met 12. Moreover, after
IRBP-specific T cell injection, Faslpr mice did not release HMGB1 in the eye or develop EAU, but intravitreous injection of
HMGB1 resulted in intraocular inflammation. Finally, tEAU in Wt mice was attenuated by local treatment with Met 12.
Unlike HMGB1, Fas-induced IL-1 and IL-18 were not essential for tEAU induction.
Conclusion: Our results show that interaction of retinal cells with infiltrating uveitogenic T cells leads to rapid release
of HMGB1 via the Fas/FasL inflammatory signaling pathway.
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Uveitis is a common cause of human visual disability and
blindness. Although the etiology remains unclear, it is gen-
erally believed that a T cell-mediated immune response
underlies the pathogenesis, and this is supported by the
observation that injection of autoreactive T cells into sus-
ceptible, syngeneic rodents induces experimental auto-
immune uveitis (tEAU) [1–4]. Moreover, studies in the
rodent models of EAU induced by immunization with a
well-characterized uveitogenic autoantigen, interphotore-
ceptor retinoid-binding protein (IRBP), have shown that
activation of autoreactive T cells is a key pathogenic event
in disease induction, progression, and recurrence [2, 5–7].
While a great deal of information is available about the
development and activation of autoimmune T cells in the
periphery in EAU, it remains unclear how only a few infil-
trating uveitogenic T cells can exert a pathogenic effect
inside the eye, an “immune privileged” site, leading to tis-
sue destruction [8, 9].
Danger signals are initiated by pathogen-associated mo-
lecular patterns (PAMPs) or damage-associated molecular
patterns (DAMPs) [10, 11], the latter being actively
secreted from inflammatory or stressed cells or pas-
sively released from damaged apoptotic or necrotic
cells. Both PAMPs and DAMPs can be recognized by
pattern-recognition receptors, including TLRs, NOD-
like receptors, retinoic acid-inducible gene-like recep-
tors, and receptors for advanced glycation end products
[10, 11]. MyD88 is an intracellular adaptor protein re-
quired for signaling by most TLRs [12]. The importance
of DAMPs in T cell-mediated uveitis was identified as a
result of our observation that in the chronic uveitis
mouse model induced by transfer of IRBP-specific T
cells (tEAU), a model induced without the use of
microbial products and resembling human chronic uve-
itis, mice lacking MyD88 (MyD88−/−) are completely
resistant to induction of tEAU [13].
In a search for DAMPs that interact with TLRs/
MyD88 in tEAU, we previously showed that HMGB1
is an early and critical mediator of IRBP-specific T
cell-induced intraocular inflammation, since HMGB1
antagonists reduce ocular inflammation by suppres-
sion of uveitogenic T cell functions, such as IRBP-
specific T cell proliferation and cytokine production
[13]. HMGB1, one of the most important DAMPs
released by cells, binds to TLR2 and 4 then MyD88 is
recruited by the TLR adaptor protein Mal [14]. We
also found that HMGB1 is actively secreted within
the eye within 24 h after IRBP-specific T cell transfer
as a consequence of direct cell-cell contact between
infiltrating IRBP-specific T cells and viable retinal
cells [13]. These results led us to search for surface
molecules expressed on IRBP-specific T cells and ret-
inal cells that mediate the secretion of HMGB1.Fas (CD95) is well studied as a death receptor that
induces apoptosis through the traditional caspase
pathway, presumably one of the mechanisms of im-
mune privilege that protect the eye from severe in-
traocular inflammation [15–17]. However, recent
studies have shown that activation of the Fas/FasL
system can also induce release of pro-inflammatory
cytokines by macrophages that are independent of
conventional caspase-mediated apoptotic signaling
[18–21]. Moreover, it was found that Fas activation
induces rapid TLR4/IRAK4-dependent release of
HMGB1, which contributes to Fas-mediated pro-
inflammatory cytokine production by viable macro-
phages [22]. In the present study, we explored
whether Fas also mediated HMGB1 secretion by
viable non-lymphoid retinal cells after interaction
with activated IRBP-specific T cells. We examined
HMGB1 release in the eye and ocular inflammation
after injection of IRBP-specific T cells from immu-
nized wild-type (Wt) B6 mice into Fas-deficient (Faslpr)
mice and also determined whether early interruption of
Fas signaling could suppress tEAU in Wt mice. Our re-
sults revealed the importance of Fas/FasL activation in the
active secretion of HMGB1 from living retinal cells and its
involvement in the early event of intraocular inflammation
triggered by uveitogenic T cells.Methods
Animals and reagents
Both on the B6 background, 8 to 10-week-old female
C57BL/6 J (B6) mice and Faslpr and IL-1 receptor-
deficient (IL-1RKO) mice were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA) and were
housed and maintained in the animal facilities of the
University of Louisville. Institutional approval was
obtained and institutional guidelines regarding animal
experimentation followed.
T cells were cultured in RPMI 1640 medium (Mediatech,
Manassas, VA, USA) supplemented with 10 % FCS
(Hyclone, Logan, UT, USA), 5 × 10−5 M 2-ME, and
100 μg/ml of penicillin/streptomycin. The human
IRBP1–20 peptide (GPTHLFQPSLVLDMAKVLLD) was
synthesized by Sigma-Aldrich (St. Louis, MO, USA).
The 12-amino acid peptide, mouse Met 12 (HHIYL-
GAVNYIY), which is a small molecular weight inhibitor
of the Fas [23, 24], and a mutant Met 12 (HHGSDHER-
NYIY) were synthesized by Genemed Synthesis (San
Antonio, TX, USA). Recombinant mouse HMGB1 was
purchased from R & D System (Minneapolis, MN,
USA). The Fas-activating mAb, Jo2, was obtained from
BD Pharmingen (San Jose, CA, USA), and the receptor-
interacting serine/threonine-protein kinase 2 (RIP2) in-
hibitor, SB203580, was obtained from Sigma.
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The method used to induce tEAU has been reported
previously [4]. Briefly, B6 mice were immunized with
IRBP1–20 in adjuvant, and 11 days later, T cells were
purified from the draining lymph nodes and spleen by
passage through a nylon wool column, then 1 × 107 cells
in 2 ml of RPMI 1640 medium were added to each well
of a six-well plate (Costar, Corning, NY, USA) and
stimulated with 20 μg/ml of IRBP1–20 in the presence of
1 × 107 irradiated syngeneic spleen cells as APCs. After
2 days, the activated lymphoblasts were isolated by gra-
dient centrifugation on Lymphoprep (Sigma-Aldrich)
and injected i.p. in 0.2 ml of PBS into naive B6 recipients
(5 × 106 cells/mouse). Experimental mice were killed on
day 15, unless stated otherwise.Histology
Inflammation of the eye was confirmed by histopath-
ology. Whole eyes were collected, immersed for 1 h in
4 % phosphate-buffered glutaraldehyde, and transferred
to 10 % phosphate-buffered formaldehyde until proc-
essed. The fixed and dehydrated tissue was embedded in
methacrylate, and 5 μm sections were cut through the
pupillary-optic nerve plane and stained with H&E. Pres-
ence or absence of disease was evaluated blind by exam-
ining six sections cut at different levels for each eye.
Severity of EAU was scored on a scale of 0 (no disease)
to 4 (maximum disease) in half-point increments based
on the presence of inflammatory cell infiltration in the
iris, ciliary body, anterior chamber, and retina [4].Intravitreous injection of Met 12 or recombinant HMGB1
HMGB1 (1 μg/eye) or PBS was injected once into the
vitreous on the same day as T cell transfer (day 0), while
Met 12 or mutant Met 12 (1 μg/eye) or PBS was injected
twice into the vitreous on days 0 and 7. The volume of
these intravitreous injections was 2 μl/eye.Isolation of retinal explants and co-culture with activated
IRBP1–20-specific T cells or Jo2
Eyes were collected from naïve Wt or Faslpr B6 mice and
the neural retina isolated and cultured as a retinal
explant as described previously [13]. Retinal explants
with the inner membrane facing up were cultured at
37 °C with 5 % CO2 for 6 h in a 24-well plate in 500 μl
of DMEM/F12 medium (Mediatech Inc, Manassas, VA,
USA) and 1 % FCS alone or containing either 1 μg/ml of
Jo2 or 5x104 activated T cells prepared from IRBP1–20-
immunized Wt B6 mice on day 11 post-injection and in-
cubated for 2 days with irradiated splenic APCs and
IRBP1–20 (10 μg/ml), then HMGB1 levels in the super-
natant were measured by ELISA, as described below.Cell necrosis assay
To ensure that measurement of HMGB1 secretion was
not confounded by nonspecific protein release due to
cell damage, cytotoxicity was quantified using a standard
measurement of lactate dehydrogenase (Sigma LDH kit).
Intraocular fluid collection
The removed eyeball was immersed in 200 μl of PBS and
cut in two, then the cornea, sclera, and lens were dis-
carded, and the rest of the tissue was cut into fine pieces.
The suspension containing the aqueous humor, vitreous
fluid, and fine pieces of tissue was centrifuged at 500 g for
5 min at 4 °C, and the supernatant immediately was stored
in a −80 °C freezer until use. Duplicate samples of about
100 μl from each eyeball were used to measure HMGB1
levels by ELISA as described below [13].
Measurement of released HMGB1 by ELISA
Protein concentrations of HMGB1 in culture supernatants
of retinal explants or intraocular fluids were determined
by ELISA kit following the manufacturer’s protocol
(USCN Life Science Inc, Missouri City, TX, USA).
Flow cytometry
For staining of FasL on enriched T cells prepared from
the spleens of naive or day 11 post IRBP-immunized B6
mice [4], aliquots of 1 × 106 cells were incubated for
30 min at 4 °C with FITC-conjugated anti-mouse CD3
Ab and phycoerythrin (PE)-conjugated anti-mouse
CD178 Ab (eBioscience) or isotype control Ab. Data col-
lection and analysis were performed on a FACSCalibur
flow cytometer (BD Biosciences, San Jose, CA, USA)
using CellQuest software (BD Biosciences).
Statistical analysis
Experiments were repeated at least three times. Statis-
tical analysis was performed using an unpaired Student’s
t test for two sets of data, one-way or two-way ANOVA
for three or more means or the Mann-Whitney U test
for the pathological score of uveitis. A P value <0.05 was
considered significant. Values determined to be signifi-
cantly different from those for controls are indicated
with asterisks in the figures (*p < 0.05; **p < 0.01).
Results
Fas agonist or IRBP-specific T cells promote HMGB1
release from viable retinal cells of Wt, but not Faslpr mice
Having previously reported that HMGB1 release from
viable retinal cells requires direct contact with activated
IRBP-specific T cells, we examined which molecules
expressed on the retinal cell surface mediate HMGB1
release. We focused on Fas, since it is expressed on the
retina [25, 26] and regulates HMGB1 release from viable
macrophages [22]. To determine whether Fas activation
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we prepared retinal explants from Wt and Faslpr mice and
treated them for 6 h with 1 ml of medium (control), an in-
flammatory cytokine cocktail (500 units of IFN-γ, 100 ng
of IL-17, 50 ng of TNF-α, 10 ng of IL-1β, and 100 ng of
IL-6), 1 μg/ml of Jo2 (a Fas-activating Ab), or 5x104 acti-
vated IRBP1–20-specific T cells from immunized Wt B6
mice; the cytokine concentrations used were those recom-
mended by the manufacturer (R & D System). As shown
in Fig. 1a, the cytokine mixture did not induce Wt retinal
explants to release more HMGB1 than medium alone,
consistent with our previous observation that HMGB1
release from retinal cells requires direct contact with acti-
vated IRBP-specific T cells [13]. However, Jo2 (Fig. 1b) or
activated IRBP-specific T cells (Fig. 1c) significantly
increased HMGB1 release by Wt retinal explants, but not
Faslpr retinal explants, indicating that the Fas/FasL inter-
action or Fas activation regulates HMGB1 release.
To check that Jo2 at 1 μg/ml triggered HMGB1 release
without cell death, we measured LDH and HMGB1 in cul-
ture supernatants of retinal explants exposed to increasing
doses of Jo2 (from 0 to 5 μg/ml) for 6 h. As shown in Fig. 2,
Jo2 starting at 0.2 μg/ml triggered significant release of
HMGB1 from retinal explants, whereas LDH was detectedFig. 1 Fas agonist or IRBP-specific T cells promoted HMGB1 release from v
from Wt B6 mice were cultured with culture medium alone (Ctrl) or contai
explants collected from Wt B6 and Faslpr mice were cultured with medium
and Faslpr mice or activated IRBP1–20-specific T cells from Wt B6 (T) were
supernatants were assayed for HMGB1 by ELISA. **p < 0.01 compared to c
representative of those obtained in three separate experiments. In each e
wells with 1 retinal explant/well from different micesignificantly high only when the retinal explant was
exposed to 5 μg/ml of Jo2. These results indicate that the
concentration of Jo2 used in this study induced Fas-
mediated HMGB1 release from retinal cells via a mechan-
ism that did not involve, or depend on, cell death.
Transfer of IRBP-specific T cells into Faslpr mice does not
lead to HMGB1 release in the eye or development of
tEAU
To demonstrate that Fas-induced HMGB1 release is im-
portant for tEAU induction, we injected activated IRBP-
specific T cells from immunized Wt B6 mice into Wt
and Faslpr mice and examined intraocular inflammation
and HMGB1 at day 15. In contrast to Wt mice, Faslps
mice exhibited no, or only very mild, ocular inflamma-
tion (Fig. 3a, b) and only very low levels of HMGB1 in
the ocular fluid (Fig. 3c).
Blockade of Fas signaling using Met 12 reduces HMGB1
release and attenuates tEAU in Wt mice
To further confirm that Fas is important for cell-cell
contact-induced HMGB1 release and to explore possible
therapy for inhibition of HMGB1 release by blocking Fas
activation, we used a novel inhibitor of the Fas pathway,iable retinal cells of Wt, but not Faslpr mice. a Retina explants collected
ning a cytokine mixture (IFN-γ, IL-17, TNF-α, IL-1β, and IL-6). b Retinal
alone or containing Jo2. c Retinal explants (R) collected from Wt B6
cultured alone or in combination (R + T). After 6 h culture of a–c,
ells cultured with medium alone by one-way ANOVA. The results are
xperiment, each control or experimental group has ≥3 individual
Fig. 2 Jo2 does not affect the viability of primary murine retinal
cells. Wt retinal explants were incubated for 6 h with medium alone
or containing increasing doses of Jo2, then HMGB1 and LDH levels
in the supernatants were measured. Values are means ± SEM of
three independent experiments. **p < 0.01 compared to retinal
explants cultured with medium alone by one-way ANOVA
Jiang et al. Journal of Neuroinflammation  (2015) 12:179 Page 5 of 10Met 12, a 12-amino acid peptide containing the YLGA
motif (HHIYLGAVNYIY) in the N-terminal region of
the extracellular domain of the α chain of Met that
binds to Fas and prevents its activation by sequestering
it [23, 24]. A mutant peptide, HHGSDHERNYIY, that
cannot bind to Fas was used as a control. As shown in
Fig. 4, Met 12 suppressed HMGB1 release from WtFig. 3 Faslpr mice do not develop ocular inflammation or release HMGB1 a
IRBP1–20-specific T cells and examined on day 15 (a–c) post-injection. a Rep
eye sections, original magnification ×100. b Pathological score for the tw
compared to Wt mice using the Mann-Whitney U test. c HMGB1 levels in
compared to naïve mice by one-way ANOVAretinal explants cultured with Jo2 (Fig. 4a), and Met 12,
but not the mutant peptide, suppressed HMGB1 release
from Wt retinal explants cultured with activated IRBP-
specific T cells (Fig. 4b). Importantly, severity of tEAU
was reduced by intravitreous, but not systemic (intra-
peritoneal), injection of Met 12 on days 0 and 7 after
IRBP-specific T cell transfer (Fig. 4c, d).
Local administration of HMGB1 restores development of
severe tEAU in Faslpr mice
To determine whether very mild ocular inflammation seen
in Faslpr mice (Fig. 3) following cell transfer was a result of
low extracellular HMGB1 levels, we injected HMGB1 or
PBS into the vitreous of Faslpr mice on the same day as
the transfer of activated IRBP1–20-specific T cells and
found that injection of HMGB1, not PBS, resulted in simi-
lar levels of intraocular inflammation to those in Wt mice
injected with IRBP1–20-specific T cells (Fig. 5).
A RIP2 inhibitor reduces Fas-induced HMGB1 release by
living retinal cells
RIP2 is a receptor-interacting serine/threonine kinase
with a C-terminal caspase activation and recruitment
domain (CARD), which contains a highly conserved
tyrosine phosphorylation site, phosphorylation of which
plays a critical role in Fas-mediated apoptosis [27]. Sincefter IRBP-specific T cell transfer. Wt and Faslpr mice were injected with
resentative ocular histopathology with H & E staining of Wt and Faslpr
o groups (n = 12 mice) presented as the mean ± SEM. **p < 0.01
the intraocular fluid (6 eye/group) measured by ELISA. **p < 0.01
Fig. 4 Blockade of Fas signaling on retinal cells in Wt mice inhibits HMGB1 release and tEAU induction. a, b Retinal explants (or R) from Wt mice
were cultured for 6 h with or without Jo2 (a) or activated IRBP1–20-specific T cells (b) in the presence or absence of 1 μg/ml of Met 12 (a, b) or
the mutant Met 12 (m) (b), then HMGB1 levels in the culture supernatant were measured by ELISA. **p < 0.01 compared to retinal explants
treated with medium by one-way ANOVA. c, d Wt mice injected with IRBP1–20-specific T cells were injected systemically (S) or intravitreously (L)
with Met 12 or PBS (Ctrl) and examined on day 15; c shows the pathological score for each group (n = 12 mice) presented as the mean ± SEM, *p
< 0.05 compared to PBS treatment using the Mann-Whitney U test, while d shows representative ocular histopathology after H & E staining, original
magnification, ×100
Fig. 5 Intravitreous injection of HMGB1 allows induction of tEAU in
Faslpr mice. Faslpr mice injected with IRBP1–20-specific T cells were
intravitreously injected with HMGB1 (1 μg/eye) or PBS (n = 9) on the
day of cell transfer and examined on day 15; Wt mice (n = 9)
injected with IRBP1–20-specific T cells were used as the positive
control. The pathological score for each group is presented as the
mean ± SEM. *<p < 0.05 compared to Wt mice injected with
IRBP1–20-specific T cells and injected intravitreously with PBS
using the Mann-Whitney U test
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ing the inflammatory function of epithelial cells [28], we
examined whether RIP2 regulated Fas-mediated HMGB1
release from live retinal cells and thus promoted ocular
inflammation by treating Wt retinal explants with Jo2 in
the presence or absence of the RIP2 inhibitor SB203580
and measured HMGB1 levels in the culture superna-
tants. As shown in Fig. 6, SB203580 significantly inhib-
ited Jo2-induced HMGB1 release from retinal explants;
similar results were observed using retinal astrocytes
treated with Jo2 with or without SB203580 (data not
shown).
Fas-induced IL-1β release is not required for development
of IRBP-specific T cell-induced intraocular inflammation
Fas activation promotes release of inflammatory cyto-
kines, such as IL-1β and IL-18 [29], both of which
recruit MyD88, an adaptor protein linking to down-
stream signaling pathways. When Wt retinal explants
were incubated with or without Jo2 for 6 h, HMGB1
(Fig. 1) and IL-1β (Fig. 7a) were detected in the culture
supernatants. Neutralizing anti-HMGB1 antibody is
Fig. 6 An RIP2 inhibitor reduces Jo2-induced HMGB1 release by Wt
retinal cells. Retinal explants from Wt mice were cultured for 6 h
with medium or medium containing 1 μg/ml of Jo2 in the presence
or absence of an RIP2 inhibitor (SB) (1 μg/ml), then HMGB1 levels in
the culture supernatants were measured by ELISA. **p < 0.01
compared to retinal explants treated with medium by
one-way ANOVA
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showing that HMGB1 is involved in this process [13];
however, in the present study, after injection of IRBP1–20-
specific T cells in IL-1RKO and IL-18KO mice, IL-1RKO
developed similar severe ocular inflammation as Wt mice
(Fig. 7b, c) so did IL-18KO mice (data not shown),Fig. 7 Fas-induced IL-1β release is not needed for tEAU induction. a Retina
(Ctrl) or medium containing 1 μg/ml of Jo2, then the culture supernatants
treated with medium alone by one-way ANOVA. b, c Wt and IL-1RKO mice
shows the pathological score for each group (n = 9 mice) presented as the
& E staining, original magnification, ×100indicating that IL-1β and IL-18 were not involved in the
effector phase of intraocular inflammation.
Discussion
The Fas/FasL system has been mainly studied for its role
in caspase-dependent, apoptotic programmed cell death
[30] to maintain tissue/cell homeostasis. Previous studies
on the eye have shown that both FasL and Fas are
expressed on ocular tissues and contribute to the im-
munologically privileged status of the eye by causing
apoptosis of invading leukocytes and protects the eye
from immune-mediated damage [15–17, 26] or play a
role in tissue damage by promoting apoptotic death of
ocular cells.[17, 31, 32]. However, the Fas/FasL system is
being increasingly recognized for its ability to trigger
inflammation [29]. Numerous studies have demonstrated
that activation of Fas signaling in a variety of non-
lymphoid cells, including colonic and lung epithelial cells
[33, 34], hepatocytes [35], synoviocytes [36], macrophages
[20], and fibroblasts [37], can lead to the expression and
release of inflammatory factors in vitro and in vivo, in par-
ticular, at the early stage of inflammation development.
Such factors may, in turn, recruit inflammatory cells,
exacerbating the inflammatory process. Accordingly, Fas/
FasL-mediated inflammation has been shown to play an
important role in the pathogenesis of several diseases,
including acute respiratory distress syndrome [34], cysticl explants collected from Wt mice were cultured for 6 h with medium
were assayed for IL-1β by ELISA. *p < 0.05 compared to retinal explants
were injected with IRBP1–20-specific T cells and examined on day 21. b
mean ± SEM and c shows representative ocular histopathology with H
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have an underlying inflammatory component. Moreover,
many chronic inflammatory diseases are attenuated in
mice lacking Fas or FasL (gld) [39, 41, 42]. For example,
compared to Wt B6 mice, gld and lpr mice are highly
resistant to the development of experimental autoimmune
encephalomyelitis (EAE) [43–45] and EAU [46],
which share essential cellular mechanisms, indicating
involvement of Fas/FasL in the T cell-mediated tissue
inflammation.
Our results clearly demonstrate that Fas is required for
active and rapid release of HMGB1 from tissue retinal cells
via cell-cell interaction with activated uveitogenic T cells.
Released HMGB1 either alone or in combination with
other pro-inflammatory mediators triggers inflammatory
cascades in the eye, probably by enhancing and sustaining
the pathogenicity of IRBP1–20-specific T cells. The in vitro
results that Fas on retinal cells mediates HMGB1 release
was further supported by our in vivo studies using Fas
knockout mice, in which transfer of IRBP1–20-specific T
cells failed to trigger HMGB1 release or induce tEAU,
while local HMGB1 injection restored susceptibility to in-
duction of ocular inflammation. These data are the first to
implicate HMGB1 in Fas-mediated HMGB1 release from
tissue cells in response to infiltrating autoreactive T cells
and provide a possible explanation for the observation that
Faslpr mice do not develop EAU after immunization with
IRBP antigen or adoptive transfer of IRBP-specific T cells
[46] (Fig. 3). The wild expression of Fas on photoreceptor
cells, retinal pigment epithelium [26], microglia [47], and
astroglia [48] of the retina correlated with the expression
pattern of HMGB1 [13]. Our study suggested that one of
the mechanisms that a few T cells initiate autoimmune
uveitis is that IRBP-specific T cells interact with parenchy-
mal cells such as residential DCs [49], microglia [50], astro-
cytes [51], and Müller cells [52], resulting in the
subsequent production of HMGB1 by those cells, mediated
by Fas/FasL, an early event in the pathogenesis of intraocu-
lar inflammation. Most adoptively transferred disease-
inducing T cells require “licensing for pathogenicity” in the
lung and other organs in order to induce disease in
target organs [53, 54]—“a hub-and-spoke pattern”
[55]. Both processes of “licensing for pathogenicity”
and of HMGB1 production could take place during
the induction of effector phase of EAU. The release
of intraocular HMGB1 on day 1 may attract the mi-
gration of “licensed” pathogenic T cells to the eye,
and the later increase of HMGB1 could be related to
the involvement of these T cells and the damage they
invoke in the retina.
The form of HMGB1 should be assessed as this has a
major effect on promotion of either pro-inflammatory
cytokine production or chemo-attraction of inflammatory
cells, although neutralization of HMGB1 inhibited tEAU.Our results complement our current understanding of the
Fas/FasL system in the eye, i.e., that it is not involved only
in induction of apoptosis of infiltrating leukocytes or tissue
cells, but also in initiation of inflammation, in particular,
during the early stage of disease development in the eye.
Different initial molecular events might lead to the activa-
tion of different molecular mechanisms resulting in the
transmission of either apoptotic or non-apoptotic signals.
The molecular process by which Fas is switched from an
inflammatory role to an apoptotic function is not known,
and the paradoxical roles of the Fas/FasL interaction in
stimulating apoptosis of invading leukocytes in the eye and
in promoting HMGB1 release and inflammation in the eye
need to be explored.
How the Fas signaling pathway triggers HMGB1
release is not known. Met 12, a 12-amino acid peptide
containing the YLGA motif in the N-terminal region of
the extracellular domain of the α chain of Met, a tyro-
sine kinase receptor for hepatocyte growth receptor, is a
small molecular weight inhibitor of Fas [23, 24] and acts
as an inhibitor of the apoptosis-activating Fas/FasL path-
way in a transformed photoreceptor cell line (661 W
cells) and in an animal model of retinal detachment [23].
We tested the inhibitory effect of Met 12 on Fas-
mediated HMGB1 release, and the subsequent intraocu-
lar inflammation and the results, shown in Figs. 4 and 5,
support our hypothesis that Fas on retinal cells mediates
HMGB1 release, which can be blocked by Met 12. Our
results showed that adoptive transfer of IRBP-specific T
cells reduced EAU severity in the Faslpr mice compared
with WT mice (Fig. 3), whereas blocking of Fas system-
ically using Met 12 did not have a similar effect on EAU
disease compared with controls (Fig. 4c). It has been
repeatedly observed that experimental results using KO
mice are frequently different when compared to blocking
agents (or antibodies). In Fas KO mice, there is both sys-
temic and intraocular deletion of Fas so that infiltrating
T cells cannot interact with Fas on parenchymal ocular
cells, resulting in inhibition of EAU. In contrast, the
dose of Met used systemically may be too low to block
Fas expressed within the eye, and/or Met administered
systemically may be degraded before entering the eye.
Support for these explanations is provided by the obser-
vation that the intraocular injection of Met does block
Fas/FasL interaction between retinal cells and infiltrating
T cells.
Another new finding was that RIP2, a receptor-
interacting serine/threonine kinase with a C-terminal cas-
pase activation and recruitment domain (CARD) that plays
a critical role in Fas-mediated apoptosis [27], is also in-
volved in Fas-mediated HMGB1 release (Fig. 6). Our find-
ing that downstream molecules of the Fas signaling
pathways, such as Met and Rip2, regulate both apoptosis
and inflammation complicates the use of pharmaceutical
Jiang et al. Journal of Neuroinflammation  (2015) 12:179 Page 9 of 10agonists or antagonists for Fas-mediated pathological
events. Further studies on the role of Fas/FasL in inflam-
mation and apoptosis in immune responses should result
in improved immunotherapies based in Fas/FasL and their
signaling molecules.
Although the Fas activator Jo2 triggered release of both
HMGB1 and IL-1 from retinal cells (Figs. 1 and 7), we have
previously shown that HMGB1 antagonists reduce intraoc-
ular inflammation induced by injection of IRBP1–20-specific
T cells [13], whereas, transfer of IRBP1–20-specific T cells
into IL-1RKO mice induced disease in all six mice (Fig. 7).
Together, these results show that HMGB1, but not IL-1, is
required for intraocular inflammation triggered by infiltrat-
ing effector autoreactive T cells. In contrast, IL-1RKO mice
are resistant to active induction of EAU by immunization
with IRBP1–20 and complete Freund’s adjuvant (data not
shown and [56, 57]. These results suggest that the IL-1R is
required for the generation of pathogenic T cells, in par-
ticular Th17 cells [58, 59] but is not needed for the subse-
quent pathogenic events occurred in the eye, i.e., in the
effector phase of EAU. Similarly, in an EAE model mice
used to study multiple sclerosis in humans, the IL-1R was
found to be required for induction of EAE by active
immunization with the antigen MOG but not for induction
of EAE induced by transfer of MOG-specific T cells [60].
Together, these results suggest that, once disease induced
by pathogenic Th17 cells has been established, reducing
IL-1 levels may not be an effective means of treatment,
whereas blockade of HMGB1 and its related signaling mol-
ecules might achieve the therapeutic goal.
Conclusion
These data demonstrate an early event in the pathogenesis
of intraocular inflammation initiated by a few infiltrating
uveitogenic T effector cells, that is, uveitogenic T cells
interact with residential APCs, leading to the subsequent
production of HMGB1 by those cells via the Fas/FasL
inflammatory signaling pathway. Blockade of HMGB1 and
its related signaling molecules might achieve the thera-
peutic goal in T cell-mediated intraocular inflammation.
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